Rebecca Marsh, MD
Infectious Disease · Hillsborough, NJNPI 1285773606
Payments from drug & device makers
Across 130 payments — averaging $18.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$693
- Merck$464
- Aimmune Therapeutics, Inc.$205
- Pfizer$194
- Gilead$168
- Smith+Nephew$106
- plus $534 from 15 others
What the payments were for
- Food & beverage$2,364100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 39 | $693 |
| Merck | 25 | $464 |
| Aimmune Therapeutics, Inc. | 6 | $205 |
| Pfizer | 12 | $194 |
| Gilead | 10 | $168 |
| Smith+Nephew | 7 | $106 |
| Johnson & Johnson | 7 | $105 |
| Shionogi Inc | 4 | $68 |
| Viiv Healthcare Company | 3 | $55 |
| Ferring Pharmaceuticals Inc. | 3 | $46 |
| Organogenesis Inc. | 2 | $40 |
| Insmed, Inc. | 2 | $37 |
| Paratek Pharmaceuticals, Inc. | 2 | $32 |
| La Jolla Pharmaceutical Company | 1 | $28 |
| Osiris Therapeutics Inc. | 1 | $22 |
| KCI USA, Inc. | 1 | $21 |
| Melinta Therapeutics, LLC | 1 | $20 |
| Theratechnologies Inc. | 1 | $19 |
| Invivyd Inc | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Cashflow Solutions, LLC | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZENPEP$125
How this compares
$2,364 in reported general payments places this provider in the 70th percentile of 334 infectious disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 18 | $7,832 |
| Cefazolin Sodium | 13 | $835 |
| Doxycycline Hyclate | 12 | $427 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Hillsborough
- Ronald NahassHillsborough$6.1M
- Robert SegalHillsborough$41K
- Rohit BhallaHillsborough$7K
- Jerry SheenHillsborough$6K
- Jihad SlimNewark$6.7M
- Bindu BalaniHackensack$4.9M
- Suraj SaggarEnglewood$2.9M
- Christopher LucastiSomers Point$2.8M
- Edward LiuNeptune$2.6M
- Keith GottesdienerRahway$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.